VAXX Vaxxinity Inc.

Biotech Analyst Ratings

Latest News

1. 09 May 2022 Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

   DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2022.
   

   "Vaxxinity has laid the groundwork to have multiple shots on goal this year after a productive and exciting start to 2022. The FDA granted Fast Track designation to our Alzheimer's vaccine candidate and we completed enrollment for our Parkinson's vaccine candidate with initial data expected in the second half of this year. We also initiated enrollment in our global pivotal Phase 3 trial of UB-612 for prevention of COVID-19 with the support of a CEPI grant," said Mei Mei Hu, CEO of Vaxxinity. "As we pursue…

   View Full Article
2. 05 May 2022 Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference

   DALLAS, May 05, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference, being held in Las Vegas, Nevada on Thursday, May 12, 2022 at 10:40 a.m. PT.
   

   A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://ir.vaxxinity.com/events-presentations, and will be available for replay for 90 days following the event.

   About Vaxxinity

   Vaxxinity, Inc. is a purpose-driven biotechnology company committed…

   View Full Article
3. 02 May 2022 Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer's Disease

   DALLAS, May 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
   

   "We are excited that the FDA has granted UB-311 Fast Track Designation, as it recognizes the evidence demonstrating the potential for UB-311 to address a serious unmet medical need for patients with Alzheimer's disease," said Mei Mei Hu, Chief Executive Officer of Vaxxinity. "We are on an encouraging clinical path for UB-311 and look forward to collaborating with the FDA and other global…

   View Full Article
4. 28 April 2022 Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson's Disease

   Results from UB-312's Part A first-in-human trials published in Movement Disorders

   DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson's disease (PD). Vaxxinity's investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to treat PD and other conditions such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).
   

   "With enrollment now complete in the second part of this two-part study, we are thrilled to take another step forward in our efforts to develop a first-of-its-kind…

   View Full Article
5. 06 April 2022 CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

   OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (NASDAQ:VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity's next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match' – booster dose. CEPI will provide up to $9.25m in funding.
   

   The Phase 3 trial, which began in the US earlier this year, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been…

   View Full Article